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Abstract
In human pancreatic myofibroblasts, interleukin (IL)-17 markedly enhances tumor necrosis factor (TNF)-a-induced IL-6 secretion
through the induction of IL-6 mRNA stabilization. Induced stability of IL-6 mRNAwas markedly decreased by the inhibitors of extracellular
signal-regulated kinase (ERKs), PD98059 and U0216. This indicates that activation of the ERK pathway is involved in the induction of IL-6
mRNA stabilization by IL-17 plus TNF-a.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Interleukin (IL)-6 has a range of biological activities
including B- and T-cell activation, stimulation of febrile
episodes, and release of acute phase response protein [1,2].
In patients with acute pancreatitis, IL-6 release occurs
during the initial stage of disease [3,4]. We have recently
found that human pancreatic myofibroblasts secrete a large
amount of IL-6 in response to IL-1h, IL-17, and tumor
necrosis factor (TNF)-a [5]. Furthermore, IL-17 markedly
enhances TNF-a-induced IL-6 production, mainly through
the induction of mRNA stabilization [5].
Three subgroups of the mitogen-activated protein (MAP)
kinase family have been identified [6–9]. The p44 and p42
extracellular signal-regulated kinase ERK1 and ERK2
responded mainly to mitogenic stimuli, while the Jun
NH2-terminal kinases (JNK) and p38 responded to cellular
stress [6–9]. Several reports have demonstrated a major role
for p38 MAP kinase in regulation of mRNA stabilization
[10–16]. The activation of p38 MAP kinase by forced
expression of MAPK kinase (MKK)-6 (an activator of
p38) or MAPK-activated protein kinase (MAPKAPK)-2 (a
downstream effector of p38) stabilizes the cyclooxigenase-2
mRNA [10,11]. A similar response has been observed in the
IL-6 and IL-8 genes [12]. A role for p38 in inducing mRNA
stabilization has also been demonstrated by the use of a
specific inhibitor of p38 MAP kinase, SB203580 [13–16].
In this study, we investigated the role of ERK1/2 MAP-
kinase in the induction of IL-6 mRNA stabilization by IL-17
and TNF-a. By using a specific inhibitor of mitogen-
activated protein kinase kinase (MEK) 1 and 2, which are
the kinases directly upstream to ERK1/2 [17,18], we dem-
onstrated that ERK1/2 play an important role in the induc-
tion of IL-6 mRNA stabilization by IL-17 plus TNF-a.
2. Materials and methods
2.1. Reagents and cells
Recombinant human IL-1h, IL-17, and TNF-a were
obtained from R&D Systems (Minneapolis, MN). The
inhibitor of MEK (PD98059 and U0216) and the inhibitor
of p38 MAPK (SB203580) were purchased from Cell
Signaling Technology (Beverly, MA) [17–19]. All other
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reagents used in this study were purchased from Sigma
Chemical Co. (St. Louis, MO). Normal human pancreatic
tissue was obtained and maintained as described in our
previous report [5].
2.2. Northern blot analysis
Northern blot was performed according to the method
described previously [5]. Stability studies were performed as
follows. Pancreatic myofibroblasts were stimulated with or
without cytokines for 3 h, washed, and further incubated
with MAP kinase inhibitors (20 AM) and actinomycin D (5
Ag/ml) for various time periods. Total RNAwas sequentially
extracted, and IL-6 mRNA abundance was determined by
Northern blotting. IL-6 mRNa abundance was expressed as
relative to the corresponding level before addition of actino-
mycin D (percent remaining). Cytokines were used at the
concentrations of IL-17 (200 ng/ml), TNF-a (10 ng/ml), and
IL-1h (0.1 ng/ml). The radioactivity of each band of North-
ern blotting was determined by the Instant Imagerk Elec-
tronic Autoradiography system model #2024/417257
(Packard, Meriden, CT). For comparison of radioactivity,
Fig. 1. Effects of IL-17 and TNF-a on IL-6 mRNA expression and IL-6
promoter activity in human pancreatic myofibroblasts. (A) The cells were
stimulated for 3 h with IL-17 (200 ng/ml), IL-1h (0.1 ng/ml), TNF-a (10
ng/ml), IL-17 plus IL-1h or IL-17 plus TNF-a, and then IL-6 mRNA
expression was determined by Northern blotting. (B) Human IL-6 promoter
DNA and h-galactosidase reporter vector were contransfected and
incubated for 24 h. Then, the cells were incubated in the presence of
stimuli further for 12 h. The luciferase activity was measured by the
Luciferase Assay System Kit (Promega) and expressed as relative activity
normalized to h-galactosidase activity. Values are expressed as meanF S.D.
(n= 4).
Fig. 2. MAP kinases activation in pancreatic periacinar myofibroblasts. The
cells were stimulated for 15 min with IL-17 (200 ng/ml), TNF-a (10 ng/ml),
or IL-17 plus TNF-a, and the phosphorylated (p ) and total MAP kinases
(ERK1/2 and p38) were sequentially detected by Western blotting.
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each radioactivity was converted to relative radioactivity to
the value of medium alone.
2.3. Western blot analysis
The cells were exposed to cytokines for 15 min, washed
with PBS, and lysed in SDS sample buffer containing 100
AM orthovanadate. Lysates were homogenized and protein
content was determined by using the Bradford method. Ten
micrograms of protein from each sample was subjected to
SDS-PAGE on a 4–20% gradient gel under reducing con-
ditions. Proteins were then electrophoretically transferred
onto a nitrocellulose membrane. The antibodies against
phosphorylated and total MAP kinases were purchased from
Cell Signaling Technology, and peroxidase-conjugated sec-
ond antibodies were purchased from Amersham (Arlington
Heights, IL). Subsequently, detection was performed using
the enhanced chemiluminescence Western blotting system
(Amersham).
2.4. IL-6 promoter luciferase reporter constructs and cell
transfection
Human IL-6 promoter region was amplified by PCR using
human genomic DNA [20] as a template with the primers: IL-
6 ( 648), ACAGGTAACTACCTGGAGACGCGTTGAA;
IL-6 ( + 66), GCTAAGCTTCTGGAGGGGAGATA-
GAGCTTC. The 5Vsequence of IL-6 ( 648) was modified
forKpnI site, and the 5Vregion of IL-6 ( + 66) wasmodified for
HindIII site, respectively. These fragments were ligated into
KpnI and HindIII sites of the luciferase reporter plasmid
pGL3-Basic (Promega, Madison, WI) yielding the reporter
construct. The sequence of inserts was determined by the
auto-sequencer. Transient transfection was performed by
using Lipofectamine Plus reagent (GIBCO BRL) according
to the manufacturer’s instruction. Twenty hours prior to
transfection, 1106 cells were plated in triplicate in 35-
mm wells of a six-well plate. For each well, 1-Ag plasmid
DNA and 0.2-Ag h-galactosidase reporter vector pCMVh
(CLONTECH, Palo Alto, CA) were cotransfected and incu-
bated for 24 h. Then, the medium was changed and cells were
incubated in the presence of stimuli further for 12 h. The
luciferase activity was measured by the Luciferase Assay
System Kit (Promega) and expressed as relative activity
normalized to h-galactosidase activity.
3. Results
In human pancreatic myofibroblasts, IL-17 markedly
enhanced TNF-a-induced IL-6 mRNA expression (Fig.
1A) [5]. To investigate the molecular mechanism involved
in this response, we initially studied how IL-17 modulates
IL-6 promoter activities. As shown in Fig. 1B, IL-17 did not
affect TNF-a-induced IL-6 promoter activity, whereas IL-17
increased IL-1h-induced IL-6 promoter activity. These
Fig. 3. Effects of MAP kinase inhibitors on the stability of TNF-a- or IL-17 induced IL-6 mRNA. Pancreatic myofibroblasts were stimulated with or without
stimulators for 3 h, washed, and further incubated with MAP-kinase inhibitors (20 AM) and actinomycin D (5 Ag/ml) for various time periods. Total RNAwas
sequentially extracted, and IL-6 mRNA abundance was determined by Northern blotting. IL-6 mRNA abundance was directly counted and expressed as
relative to the corresponding level before addition of actinomycin D (percent remaining). Cytokines were used at the concentrations of IL-17 (200 ng/ml) and
TNF-a (10 ng/ml).
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results are compatible with our previous observation that IL-
17 did not affect TNF-a-induced NF-nB activation, which
plays a critical role in the induction of the IL-6 gene. Taken
together, these observations indicate that transcriptional
mechanism does not play a major role in the strong enhance-
ment of IL-6 gene expression by the combination of IL-17
plus TNF-a.
As shown in Fig. 2, IL-17, TNF-a, or IL-17 plus TNF-a
induced ERK or p38 MAP kinase phosphorylation. The
combination of IL-17 plus TNF-a enhanced ERK and p38
phosphorylation as compared to the effect of either TNF-a
of IL-17 alone.
To investigate the role of MAP kinases in the induction
of IL-6 mRNA stabilization by IL-17 or TNF-a, we used
MAP kinase inhibitors. SB203580 is an inhibitor of p38
MAP kinase [19]. PD98059 and U0216 are inhibitors of
MEK, which is an upstream activator of ERK MAP kinase
[17,18]. PD98059 is specific for MEK1, and U0216 is
specific for MEK1 and MEK2 [17,18]. Inhibition of ERK
activity by U0216 is stronger than that induced by
PD98059. As shown in Fig. 3, IL-6 mRNA induced by
TNF-a or IL-17 was rapidly decreased within 3 h, and the
addition of MAP inhibitors dramatically enhanced the rate
of IL-6 mRNA decay. These observations indicate that the
posttranscriptional regulation mediated by MAP kinase
activation is important in the induction of IL-6 mRNA by
either TNF-a or IL-17 alone.
As shown in Fig. 4, the IL-6 mRNA induced by IL-17
plus TNF-a was stable within 5 h. The addition of
SB203580 completely blocked IL-17-induced IL-6 mRNA
stability. This response was compatible with the previous
reports demonstrating the role of the p38 MAP kinase
pathway in the induction of mRNA stability [10–16].
Similarly, the addition of PD98059 partially inhibited IL-
17 plus TNF-a-induced IL-6 mRNA stabilization and
U0216 exerted complete inhibition, indicating that the
ERK1/2 MAP kinase pathway is involved in the induction
of IL-6 mRNA stabilization by IL-17 plus TNF-a.
4. Discussion
IL-17 is a newly identified T cell-specific cytokine [21–
26]. There is increasing evidence that IL-17 is a mediator of
inflammatory responses in various tissues through activation
of the NF-nB and MAP kinase pathways [5]. IL-6 induction
by IL-17 in pancreatic periacinar myofibroblasts suggests a
role for T cells in the pathogenesis of acute pancreatitis [5].
The most important finding of the present study is that
inhibition of ERK 1/2 kinase activity markedly reduced the
stability of the IL-6 mRNA induced by IL-17 plus TNF-a.
U0216 is an inhibitor of MEK1 and MEK2, and PD98059 is
an inhibitor of MEK1 [17,18]. As demonstrated previously
[5], U0216 exerted a stronger inhibitory effects than
PD98059 in the cells used in this study. Consistent with
the activities of MAP kinase inhibition, U0216 blocked IL-
17 plus TNF-a-induced IL-6 mRNA stabilization more
strongly than PD98059, indicating that inhibition of
ERK1/2 activity was actually correlated with the destabili-
zation of IL-6 mRNA. In addition, the induction of mRNA
stability might be the major mechanism accounting for the
IL-17 plus TNF-a-induced increase in IL-6 secretion, since
IL-17 did not affect TNF-a-induced IL-6 promoter activity.
The p38 MAP kinase has been reported to play a major
role in the induction of mRNA stabilization through AU-
rich elements in the 3V-untranslated regions [10–12]. Recent
studies demonstrate that ERK MAP kinase is also involved
in the induction of mRNA stabilization [27–29]. AUUUA
sequences repeated in the 3V-untranslated region of many
cytokine genes were target for rapid degradation and
inhibited the translation of the corresponding mRNAs
[10–12]. Six copies of the AUUUA sequences are located
in the 3V-untranslated region of IL-6 mRNA [13]. The p38
Fig. 4. Effects of MAP kinase inhibitors on the stability of TNF-a plus IL-
17 induced IL-6 mRNA. IL-6 mRNA stability was assessed by the method
described in Materials and methods. Cytokines were used at the con-
centrations of IL-17 (200 ng/ml) and TNF-a (10 ng/ml), and MAP kinase
inhibitors were used at 20 AM.
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MAP kinase or its downstream kinases are considered to
affect the proteins that bind to the AUUUA sequence of IL-6
mRNA and induce stabilization. Actually, several mole-
cules, such as AUBF, have been identified which bind
AU-rich sequences to increase mRNA stability [30].
Accordingly, a protein that destabilizes mRNA was gener-
ated rapidly after stimulation, and this action was blocked
by the activated p38 MAP kinase [13]. A similar mecha-
nism might be involved in ERK-mediated IL-6 mRNA
stabilization, since Sirenco et al. [30] previously reported
that formation of the AUUUA sequence-binding complexes
and accelerated mRNA turnover involve protein phosphor-
ylation processes. Although they did not provide direct
evidence that ERK1/2 MAP kinase participates in the
induction of IL-1h and GRO mRNA stabilization, it was
suggested that the activation of tyrosine kinase, as well as
p38 MAP kinase, might be involved.
In conclusion, the present study indicates that ERK MAP
kinase is involved in the induction of IL-6 mRNA stability
by IL-17 plus TNF-a. The mechanism mediating mRNA
stabilization suggests a central role for p38 MAP kinase, but
the mechanisms by which ERK MAP kinase induces the
stabilization of IL-6 mRNA require further investigation.
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